文献速递消化系统肿瘤

KRAS野生型胰腺癌中的NRG1融合

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2018-05-25

研究对17例胰腺导管腺癌患者进行全基因组和转录组测序,发现4例KRAS野生型肿瘤均存在可被小分子酪氨酸激酶抑制剂抑制的基因融合,包括复发性NRG1重排。2例NRG1重排且对标准治疗耐药的患者接受ERBB抑制后临床改善并肝转移缓解,提示系统筛查KRAS野生型肿瘤的致癌融合基因可改善治疗前景。

要点

  • KRAS野生型胰腺癌中可检出NRG1融合等可靶向基因重排。
  • NRG1重排通过异常ERBB受体信号驱动胰腺癌发生。
  • ERBB抑制使2例NRG1重排耐药患者临床改善并肝转移缓解。

核心结论

  • KRAS野生型胰腺癌中复发性NRG1融合等基因重排是疾病驱动事件,系统筛查可改善治疗前景。

研究设计与样本

  • 对17例入组精准肿瘤学项目的胰腺导管腺癌年轻患者行全基因组和转录组测序。

主要发现

  • 17例中4例为KRAS野生型肿瘤,均存在可被小分子酪氨酸激酶抑制剂抑制的基因融合。
  • 这些改变包括复发性NRG1重排,预测通过异常ERBB受体介导信号驱动胰腺癌发生。
  • 2例NRG1重排且对标准治疗耐药的患者接受ERBB抑制后临床改善并肝转移缓解。

关键数值与推荐

  • KRAS野生型肿瘤4例均存在可靶向基因融合,占17例中的4例。
  • NRG1重排患者中2例接受ERBB抑制后临床改善并肝转移缓解。

临床怎么用

  • 对KRAS野生型胰腺癌系统筛查致癌融合基因,以识别可接受酪氨酸激酶抑制剂治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC). Molecular characterization of 17 patients with PDAC enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASWT) tumors (4 of 17). These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in 2 patients with NRG1-rearranged tumors that had proved resistant to standard treatment. Our findings demonstrate that systematic screening of KRASWT tumors for oncogenic fusion genes will substantially improve the therapeutic prospects for a sizeable fraction of patients with PDAC.Significance: Advanced PDAC is a malignancy with few treatment options that lacks molecular mechanism-based therapies. Our study uncovers recurrent gene rearrangements such as NRG1 fusions as disease-driving events in KRASwt tumors, thereby providing novel insights into oncogenic signaling and new therapeutic options in this entity. Cancer Discov; 8(9); 1087-95. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Heining C, Horak P, Uhrig S, et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018. PMID: 29802158. doi:10.1158/2159-8290.CD-18-0036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。